WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/083906    International Application No.:    PCT/US2006/003461
Publication Date: 10.08.2006 International Filing Date: 01.02.2006
A61K 38/04 (2006.01)
Applicants: ATTENUON, LLC [US/US]; 11535 Sorrento Valley Rd., Suite 401, San Diego, CA 92121 (US) (For All Designated States Except US).
MAZAR, Andrew, P [US/US]; (US) (For US Only).
HEIATI, Hashem [US/US]; (US) (For US Only).
SCHRIER, Jay [US/US]; (US) (For US Only).
LI, Ming [US/US]; (US) (For US Only).
HARRIS, Scott [US/US]; (US) (For US Only)
Inventors: MAZAR, Andrew, P; (US).
HEIATI, Hashem; (US).
LI, Ming; (US).
HARRIS, Scott; (US)
Agent: LIVNAT, Shmuel; McKenna Long & Aldridge LLP, 1900 K Street, N.W., Washington, DC 20006 (US)
Priority Data:
60/648,391 01.02.2005 US
Abstract: front page image
(EN)Described herein are compositions/formulations of the Cys-containing anti-angiogenic peptide Pro-His-Ser-Cys-Asn (preferably in its capped form as Ac-PHSCN-NH2) or acid addition salts thereof or analogue thereof, that comprise at least one additional compound that stabilizes the peptide or analogue against spontaneous tandem dimerization or higher oligomerization. Preferred formulations include an acidic buffer such as citrate, glycine as an excipient and bulking agent. Optional additional components of the formulation are a reducing agent, a non-thiol biocompatible anti-oxidant, a lyoprotectant (typically one or more sugars, one or more amino acids, one or more methylamine, one or more lyotropic salts, and/or one or more polyols. Also provided is an article of manufacture or kit comprising the formulation in solution or in lyophilized form. A method of inhibiting angiogenesis in a subject, comprising administering to the subject the peptide in the above formulation is also disclosed.
(FR)L'invention concerne des compositions/préparations du peptide Pro-His-Ser-Cys-Asn anti-angiogénique contenant une cystéine (de préférence sous sa forme coiffée Ac-PHSCN-NH2) ou de sels d'addition d'acide dudit peptide ou d'un analogue dudit peptide, comprenant au moins un composé supplémentaire qui stabilise le peptide ou un analogue contre la dimérisation en tandem spontanée ou l'oligomérisation plus élevée. Les préparations préférées comprennent un tampon acide tel que du citrate, de la glycine en tant qu'excipient et agent gonflant. Les constituants supplémentaires éventuels de la préparation sont un agent réducteur, un anti-oxydant biocompatible non thiol, un lyoprotecteur (généralement un ou plusieurs sucres, un ou plusieurs acides aminés, une ou plusieurs méthylamines, un ou plusieurs sels lyotropiques, et/ou un ou plusieurs polyols. L'invention concerne également un article manufacturé ou un nécessaire comprenant la préparation en solution ou sous forme lyophilisée. L'invention concerne enfin un procédé d'inhibition de l'angiogenèse chez un sujet, consistant à administrer au sujet le peptide contenu dans la préparation susmentionnée.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)